Lilly Asia Ventures returned to take part in a series B round led by Access Industries unit Access Biotechnology that took Passage Bio's funding to $226m to date.

US-based genetic medicine developer Passage Bio completed a $110m series B round yesterday led by Access Biotechnology, the life sciences investment vehicle for diversified conglomerate Access Industries. Lilly Asia Ventures, a corporate venturing subsidiary of pharmaceutical firm Eli Lilly, also took part, as did OrbiMed, Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.